Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC

NCT00469443 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

330

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer

Interventions

DRUG: Irinotecan
DRUG: 5-Fluorouracil
DRUG: Leucovorin
DRUG: Capecitabine
DRUG: Bevacizumab
DRUG: Bevacizumab
DRUG: Irinotecan

Sponsor

Hellenic Oncology Research Group

Collaborators

[object Object]